Vaspin Increases Nitric Oxide Bioavailability through the Reduction of Asymmetric Dimethylarginine in Vascular Endothelial Cells

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Jung, Chang Hee ^a   Lee, Woo Je ^a   Hwang, Jenie Yoonoo ^a   Lee, Min Jung ^a   Seol, So Mi ^a   Kim, Yun Mi ^a   Lee, Yoo La ^a   Kim, Hyun Sik ^a   Kim, Min Seon ^a   Park, Joong Yeol ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID; N(G),N(G) DIMETHYLARGININE; SERINE; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASPIN;

AMINO ACID METABOLISM; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; ENZYME SYNTHESIS; GENE ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; VASODILATATION;

ANIMALS; ARGININE; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTHELIAL CELLS; HUMANS; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SERPINS;

RATTUS;

EID: 84871693810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052346     Document Type: Article

References (51)

1. Andrew PJ, Mayer B, (1999) Enzymatic function of nitric oxide synthases. Cardiovasc Res 43: 521-531.
2. Naseem KM, (2005) The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 26: 33-65.
3. Kawashima S, Yokoyama M, (2004) Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 24: 998-1005.
4. Tran CT, Leiper JM, Vallance P (2003) The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4: 33-40.
5. Chan NN, Chan JC, (2002) Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 45: 1609-1616.
6. Boger RH, (2003) Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 41: 1467-1472.
7. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, et al. (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99: 3092-3095.
8. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, et al. (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106: 987-992.
9. Hida K, Wada J, Eguchi J, Zhang H, Baba M, et al. (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 102: 10610-10615.
10. Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, et al. (2011) Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 413: 264-269.
11. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, et al. (2002) all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 90: 764-769.
12. Malin DH, Lake JR, Shenoi M, Upchurch TP, Johnson SC, et al. (1998) The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 140: 371-377.
13. Won JC, Park JY, Kim YM, Koh EH, Seol S, et al. (2010) Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha overexpression prevents endothelial apoptosis by increasing ATP/ADP translocase activity. Arterioscler Thromb Vasc Biol 30: 290-297.
14. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, et al. (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269: 81-83.
15. Zanetti M, Sato J, Katusic ZS, O'Brien T, (2001) Gene transfer of superoxide dismutase isoforms reverses endothelial dysfunction in diabetic rabbit aorta. Am J Physiol Heart Circ Physiol 280: H2516-2523.
16. Dudzinski DM, Michel T, (2007) Life history of eNOS: partners and pathways. Cardiovasc Res 75: 247-260.
17. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, et al. (2000) Vasodilator-Stimulated Phosphoprotein Serine 239 Phosphorylation as a Sensitive Monitor of Defective Nitric Oxide/cGMP Signaling and Endothelial Dysfunction. Circulation Research 87: 999-1005.
18. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, et al. (1997) Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100: 1230-1239.
19. Lee WJ, Song KH, Koh EH, Won JC, Kim HS, et al. (2005) Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 332: 885-891.
20. Phalitakul S, Okada M, Hara Y, Yamawaki H, (2011) Vaspin prevents TNF-α-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-κB and PKCθ activation in cultured rat vascular smooth muscle cells. Pharmacol Res 64: 493-500.
21. Phalitakul S, Okada M, Hara Y, Yamawaki H, (2012) A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun 423: 844-849.
22. Wadham C, Mangoni AA, (2009) Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease. Expert Opin Drug Metab Toxicol 5: 303-319.
23. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, et al. (1999) Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343 Pt 1: 209-214.
24. Paiva H, Laakso J, Laine H, Laaksonen R, Knuuti J, et al. (2002) Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 40: 1241-1247.
25. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, et al. (1996) Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 119: 1533-1540.
26. Lee WJ, Kim SW, Kim SH, Kim GH, Han SM, et al. (2010) Alpha-lipoic acid activates dimethylarginine dimethylaminohydrolase in cultured endothelial cells. Biochem Biophys Res Commun 398: 653-658.
27. Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, et al. (2012) Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 81: 762-768.
28. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, et al. (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847.
29. Tan B, Jiang DJ, Huang H, Jia SJ, Jiang JL, et al. (2007) Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vascul Pharmacol 46: 338-345.
30. Yin QF, Xiong Y, (2005) Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol 45: 525-532.
31. Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL, et al. (2005) Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol 371: 401-407.
32. Hegyi K, Fulop K, Kovacs K, Toth S, Falus A, (2004) Leptin-induced signal transduction pathways. Cell Biol Int 28: 159-169.
33. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, et al. (2005) Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 174: 3925-3931.
34. Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, et al. (2004) Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10: 168-174.
35. Matsukawa A, Kudo S, Maeda T, Numata K, Watanabe H, et al. (2005) Stat3 in resident macrophages as a repressor protein of inflammatory response. J Immunol 175: 3354-3359.
36. Sherman CT, Brasier AR, (2001) Role of signal transducers and activators of transcription 1 and-3 in inducible regulation of the human angiotensinogen gene by interleukin-6. Mol Endocrinol 15: 441-457.
37. Wang M, Zhang W, Crisostomo P, Markel T, Meldrum KK, et al. (2007) Endothelial STAT3 plays a critical role in generalized myocardial proinflammatory and proapoptotic signaling. Am J Physiol Heart Circ Physiol 293: H2101-2108.
38. Fu XY, (2006) STAT3 in immune responses and inflammatory bowel diseases. Cell Res 16: 214-219.
39. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, et al. (1997) Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A 94: 3801-3804.
40. Kira M, Sano S, Takagi S, Yoshikawa K, Takeda J, et al. (2002) STAT3 deficiency in keratinocytes leads to compromised cell migration through hyperphosphorylation of p130(cas). J Biol Chem 277: 12931-12936.
41. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, et al. (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
42. Zhang X, Shan P, Jiang G, Zhang SS, Otterbein LE, et al. (2006) Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury. FASEB J 20: 2156-2158.
43. Kano A, Wolfgang MJ, Gao Q, Jacoby J, Chai GX, et al. (2003) Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J Exp Med 198: 1517-1525.
44. Cho JK, Han TK, Kang HS, (2010) Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol 108: 347-353.
45. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, et al. (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57: 372-377.
46. Koiou E, Tziomalos K, Dinas K, Katsikis I, Kalaitzakis E, et al. (2011) The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J 58: 237-246.
47. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, et al. (2008) Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 57: 1501-1507.
48. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, et al. (2011) Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta 412: 48-52.
49. Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, et al. (2011) Plasma Vaspin Concentrations Are Elevated in Metabolic Syndrome in Men and Are Correlated with Coronary Atherosclerosis in Women. Clin Endocrinol (Oxf).
50. Wada J, (2008) Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 17: 327-333.
51. Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, et al. (2012) Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J Clin Endocrinol Metab 97: E1202-1207.